Asahi Kasei Corp

Discover how microcrystalline cellulose drives growth in pharma and clean‑label foods—high‑performance, sustainable MCC solutions from Asahi Kasei and global market trends.

Asahi Kasei’s shares climb modestly amid a bullish Nikkei and strong Japanese current‑account surplus, showing resilience to rising oil costs and U.S. inflation concerns.

Asahi Kasei’s FY 2024 earnings rise, with EPS up, strong margins, and ¥3 trillion sales—driven by polymer, chemical and electronic‑material growth. Read how the conglomerate outperforms rivals.

Asahi Kasei partners with Patlytics’ AI platform to speed patent filings, cut drafting time by 30‑40 % and sharpen infringement analysis for smarter IP strategy.

Asahi Kasei dominates the growing cellulose‑gel market with plant‑based, clean‑label solutions, AI‑driven production, and Asia‑Pacific expansion, driving 7% revenue growth by 2033.

Asahi Kasei launches a GMP‑validated viral‑safety test using Oxford Nanopore sequencing—speed, breadth, and regulatory compliance in one rapid assay for biopharma.

Asahi Kasei thrives on growing sodium‑cyanide demand and expanding low‑VOC emulsion‑polymer markets, offering undervalued growth driven by green‑energy trends and regulatory shifts.

Asahi Kasei’s new partnership with Alchemedicine unlocks HiSAP drug‑lead compounds, blending polymer chemistry with high‑throughput screening for potential high‑margin biopharma growth.

Asahi Kasei launches a CO₂ indoor‑air‑quality sensor and its Veloxis sub‑company gets FDA orphan‑drug status for a transplant drug—showing a smart, multi‑sector innovation strategy that diversifies revenue while tapping growth in IAQ and niche thera…

Asahi Kasei ends HMD production to focus on higher‑margin specialty polymers, capitalising on circular‑economy trends and reducing regulatory risk while diversifying into real‑estate and healthcare.